Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

According to Needham, Lucid Diagnostics Inc. LUCD is likely to receive approval for EsoGuard testing-related Medicare reimbursement, which would boost testing volumes.The Lucid Diagnostics Analyst: Analyst Mike Matson maintained a Buy rating and price target of $3.The Lucid Diagnostics Thesis: The company completed over 25,000 cumulative EsoGuard tests (DNA tests) through the fourth quarter of 2024 and filed for Medicare reimbursement, which is expected to come through in the first half of 2025, Matson said ...